Namandje  Bumpus net worth and biography

Namandje Bumpus Biography and Net Worth

Dr. Namandjé N. Bumpus served as the FDA’s Principal Deputy Commissioner until December 31, 2024, after joining the agency in August 2022 as Chief Scientist. As Principal Deputy Commissioner she played a pivotal role in shaping the agency’s strategic direction and driving its day-to-day operations. She worked closely with the FDA Commissioner to spearhead key public health initiatives, strengthening regulatory frameworks, modernizing enterprise systems, and enhancing laboratory testing capabilities. She was also one of the foremost drivers of strategy for integration of AI into regulatory science at the agency. Prior to the FDA, Dr. Bumpus was an endowed professor and chair of the Department of Pharmacology and Molecular Sciences at Johns Hopkins University School of Medicine, where she also served as an associate dean. She earned a Ph.D. in pharmacology from the University of Michigan and completed a postdoctoral fellowship at The Scripps Research Institute. Her prior research has spanned across drug metabolism, drug-induced toxicity, mass spectrometry, and infectious disease pharmacology. Dr. Bumpus has received several honors, including the Presidential Early Career Award, the John J. Abel Award, and the Leon I. Goldberg Award, and is a fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine.

What is Namandje Bumpus' net worth?

The estimated net worth of Namandje Bumpus is at least $164.05 thousand as of June 3rd, 2026. Dr. Bumpus owns 43,171 shares of Recursion Pharmaceuticals stock worth more than $164,050 as of June 5th. This net worth approximation does not reflect any other investments that Dr. Bumpus may own. Learn More about Namandje Bumpus' net worth.

How do I contact Namandje Bumpus?

The corporate mailing address for Dr. Bumpus and other Recursion Pharmaceuticals executives is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. Recursion Pharmaceuticals can also be reached via phone at 385-269-0203 and via email at [email protected]. Learn More on Namandje Bumpus' contact information.

Has Namandje Bumpus been buying or selling shares of Recursion Pharmaceuticals?

Within the last three months, Namandje Bumpus has sold $15,526.44 in Recursion Pharmaceuticals stock. Most recently, Namandje Bumpus sold 4,386 shares of the business's stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $3.54, for a transaction totalling $15,526.44. Following the completion of the sale, the director now directly owns 43,171 shares of the company's stock, valued at $152,825.34. Learn More on Namandje Bumpus' trading history.

Who are Recursion Pharmaceuticals' active insiders?

Recursion Pharmaceuticals' insider roster includes Blake Borgeson (Director), Namandje Bumpus (Director), Terry-Ann Burrell (Director), Zavain Dar (Director), Christopher Gibson (CEO), Najat Khan (Insider), Tina Larson (COO), Dean Li (Director), Tina Marriott (President & COO), Michael Secora (CFO), Ben Taylor (CFO), and Shafique Virani (Chief Corporate Development Officer). Learn More on Recursion Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Recursion Pharmaceuticals?

In the last year, insiders at the sold shares 13 times. They sold a total of 986,451 shares worth more than $4,172,272.31. The most recent insider tranaction occured on June, 3rd when Director Namandje Bumpus sold 4,386 shares worth more than $15,526.44. Insiders at Recursion Pharmaceuticals own 8.4% of the company. Learn More about insider trades at Recursion Pharmaceuticals.

Information on this page was last updated on 6/3/2026.

Namandje Bumpus Insider Trading History at Recursion Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/3/2026Sell4,386$3.54$15,526.4443,171View SEC Filing Icon  
See Full Table

Namandje Bumpus Buying and Selling Activity at Recursion Pharmaceuticals

This chart shows Namandje Bumpus's buying and selling at Recursion Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Recursion Pharmaceuticals Company Overview

Recursion Pharmaceuticals logo
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Read More

Today's Range

Now: $3.41
Low: $3.38
High: $3.70

50 Day Range

MA: $3.30
Low: $2.84
High: $3.80

2 Week Range

Now: $3.41
Low: $2.77
High: $7.18

Volume

9,492,525 shs

Average Volume

17,224,771 shs

Market Capitalization

$1.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04